每周自适应放疗对比标准调强放疗在头颈癌中的成本效果分析:ARTIX试验
ARTIX随机多中心试验比较每周重新计划的自适应放疗(ART)与标准IMRT,ART旨在纠正腮腺过量照射以减少口干。129例患者中127例链接法国国家健康数据系统。12个月时ART组人均总成本€41,564(SD 23,624)高于标准IMRT组€33,063(SD 16,886),p=0.033;每避免一例口干的增量成本效果比为€162,444。结论认为ART策略对局部晚期口咽癌患者相比标准IMRT不具有成本效果。
要点
- 12个月时ART组人均总成本€41,564(SD 23,624)vs 标准IMRT组€33,063(SD 16,886),p=0.033。
- 每避免一例口干的ICER为€162,444(12个月)和€194,521(24个月)。
- 无进展生存和总生存方面,ART被标准IMRT支配。
核心结论
- ART策略对局部晚期口咽癌患者相比标准IMRT不具有成本效果。
研究设计与样本
- ARTIX试验为随机、平行组、多中心研究,比较系统性每周重新计划的自适应放疗与标准IMRT。
- 成本效果分析基于ARTIX试验并与法国国家健康数据系统(SNDS)链接,每例患者的医疗消费和成本由SNDS提供。
- 参考案例分析基于试验主要终点,并进行敏感性和情景分析。
主要发现
- 2013年至2018年随机分配的129例患者中,仅2例记录未链接至SNDS,链接比例为98.4%。
- 其余127例记录链接稳健性良好至非常好。
- 12个月意向治疗人群中,ART组人均总成本€41,564(SD 23,624),标准IMRT组€33,063(SD 16,886),p=0.033。
- 每避免一例口干的ICER为€162,444(12个月)和€194,521(24个月)。
- 无进展生存和总生存方面,ART被标准IMRT支配。
关键数值与推荐
- 主要终点为12个月时口干频率,通过石蜡刺激唾液流率测量。
- 12个月意向治疗人群人均总成本:ART组€41,564(SD 23,624)vs 标准IMRT组€33,063(SD 16,886),p=0.033。
- ICER为每避免一例口干€162,444(12个月)和€194,521(24个月)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: We performed a cost-effectiveness analysis (CEA) comparing an adaptive radiotherapy (ART) strategy, based on weekly replanning, aiming to correct the parotid gland overdose during treatment and expecting therefore to decrease xerostomia, when compared to a standard IMRT. MATERIALS AND METHODS: We conducted the ARTIX trial, a randomized, parallel-group, multicentric study comparing a systematic weekly replanning ART to a standard IMRT. The primary endpoint was the frequency of xerostomia at 12 months, measured by stimulating salivary flow with paraffin. The CEA was designed alongside the ARTIX trial which was linked to the French national health data system (SNDS). For each patient, healthcare consumptions and costs were provided by the SNDS. The reference case analysis was based on the primary endpoint of the trial. Sensitivity and scenario analyses were performed. RESULTS: Of the 129 patients randomly assigned between 2013 and 2018, only 2 records were not linked to the SNDS, which provides a linkage proportion of 98.4%. All of the other 127 records were linked with good to very good robustness. On the intent-to-treat population at 12 months, mean total costs per patient were €41,564 (SD 23,624) and €33,063 (SD 16,886) for ART and standard IMRT arms, respectively (p = 0.033). Incremental cost effectiveness ratio (ICER) was €162,444 per xerostomia avoided. At 24 months, ICER was €194,521 per xerostomia avoided. For both progression-free and overall survival, ART was dominated by standard IMRT. CONCLUSION: The ART strategy was deemed to be not cost-effective compared with standard IMRT for patients with locally advanced oropharyngeal cancer.
引用
- Perrier L, Balusson F, Morelle M, et al. Cost-effectiveness of weekly adaptive radiotherapy versus standard IMRT in head and neck cancer alongside the ARTIX trial. Radiother Oncol. 2024. PMID: 38316193. doi:10.1016/j.radonc.2024.110116
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。